Key Points
- CEO Xingjuan Chao sold 20,846 CeriBell shares at an average price of $25.03, generating $521,775.38. After the transaction, Chao retained 746,345 shares valued at approximately $18.7 million.
- Chao has made several additional sales since July, totaling more than 118,000 shares across the disclosed transactions, while CeriBell’s stock has risen to around $25—near its 52-week high of $25.63.
- Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $24.40 price target, despite the company reporting a quarterly EPS loss of $0.51 and forecasting a full-year loss.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CFO Scott Blumberg sold 846 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $25.00, for a total transaction of $21,150.00. Following the completion of the transaction, the chief financial officer directly owned 146,600 shares of the company's stock, valued at $3,665,000. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Scott Blumberg also recently made the following trade(s):
- On Wednesday, September 2nd, Scott Blumberg sold 652 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $16,300.00.
- On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $36,534.42.
- On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total transaction of $838,805.36.
- On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $24,750.00.
CeriBell Trading Up 2.0%
NASDAQ:CBLL opened at $25.00 on Friday. The stock has a 50-day simple moving average of $21.51 and a 200-day simple moving average of $19.79. The stock has a market cap of $959.50 million, a P/E ratio of -14.20 and a beta of 0.95. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.63. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on CBLL shares. Barclays raised shares of CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. Weiss Ratings upgraded shares of CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday. BTIG Research reissued a "buy" rating and issued a $30.00 target price on shares of CeriBell in a report on Friday, September 11th. Canaccord Genuity Group boosted their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CeriBell presently has an average rating of "Moderate Buy" and an average price target of $24.40.
Check Out Our Latest Analysis on CeriBell
Institutional Investors Weigh In On CeriBell
A number of institutional investors have recently added to or reduced their stakes in CBLL. Strs Ohio acquired a new stake in CeriBell during the 1st quarter worth approximately $27,000. Legal & General Group Plc acquired a new position in CeriBell during the second quarter valued at approximately $53,000. Caitong International Asset Management Co. Ltd grew its stake in CeriBell by 8,735.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company's stock worth $60,000 after buying an additional 2,708 shares during the period. Larson Financial Group LLC increased its position in shares of CeriBell by 1,403.1% in the fourth quarter. Larson Financial Group LLC now owns 2,871 shares of the company's stock worth $63,000 after acquiring an additional 2,680 shares in the last quarter. Finally, State of Wyoming purchased a new position in shares of CeriBell in the 1st quarter valued at $62,000.
CeriBell Company Profile
(
Get Free Report)
Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.
The company's primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
